JP2019533651A5 - - Google Patents

Download PDF

Info

Publication number
JP2019533651A5
JP2019533651A5 JP2019517236A JP2019517236A JP2019533651A5 JP 2019533651 A5 JP2019533651 A5 JP 2019533651A5 JP 2019517236 A JP2019517236 A JP 2019517236A JP 2019517236 A JP2019517236 A JP 2019517236A JP 2019533651 A5 JP2019533651 A5 JP 2019533651A5
Authority
JP
Japan
Prior art keywords
cancer
subject
administering
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019517236A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533651A (ja
JP6801093B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/055660 external-priority patent/WO2018068021A1/en
Publication of JP2019533651A publication Critical patent/JP2019533651A/ja
Publication of JP2019533651A5 publication Critical patent/JP2019533651A5/ja
Application granted granted Critical
Publication of JP6801093B2 publication Critical patent/JP6801093B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019517236A 2016-10-07 2017-10-06 グルココルチコイド受容体の阻害剤 Active JP6801093B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662405801P 2016-10-07 2016-10-07
US62/405,801 2016-10-07
US201762526331P 2017-06-28 2017-06-28
US62/526,331 2017-06-28
PCT/US2017/055660 WO2018068021A1 (en) 2016-10-07 2017-10-06 Inhibitors of glucocorticoid receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020191820A Division JP2021046409A (ja) 2016-10-07 2020-11-18 グルココルチコイド受容体の阻害剤

Publications (3)

Publication Number Publication Date
JP2019533651A JP2019533651A (ja) 2019-11-21
JP2019533651A5 true JP2019533651A5 (enExample) 2020-08-06
JP6801093B2 JP6801093B2 (ja) 2020-12-16

Family

ID=61832215

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019517236A Active JP6801093B2 (ja) 2016-10-07 2017-10-06 グルココルチコイド受容体の阻害剤
JP2020191820A Ceased JP2021046409A (ja) 2016-10-07 2020-11-18 グルココルチコイド受容体の阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020191820A Ceased JP2021046409A (ja) 2016-10-07 2020-11-18 グルココルチコイド受容体の阻害剤

Country Status (20)

Country Link
US (5) US10472387B2 (enExample)
EP (2) EP3523315B1 (enExample)
JP (2) JP6801093B2 (enExample)
KR (2) KR102237916B1 (enExample)
CN (2) CN110099915A (enExample)
AU (3) AU2017339510B2 (enExample)
BR (1) BR112019006987B1 (enExample)
CA (1) CA3039636C (enExample)
DK (1) DK3523315T3 (enExample)
ES (1) ES2867853T3 (enExample)
HU (1) HUE054542T2 (enExample)
IL (2) IL265835B (enExample)
MX (2) MX385658B (enExample)
NZ (1) NZ753142A (enExample)
PL (1) PL3523315T3 (enExample)
PT (1) PT3523315T (enExample)
SG (1) SG11201903055UA (enExample)
SI (1) SI3523315T1 (enExample)
WO (1) WO2018068021A1 (enExample)
ZA (1) ZA202004440B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017112909A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
JP6906525B2 (ja) 2015-12-23 2021-07-21 オリック ファーマシューティカルズ,インク. グルココルチコイド受容体の阻害剤
CN110099915A (zh) 2016-10-07 2019-08-06 欧瑞克制药公司 糖皮质激素受体抑制剂
WO2019200156A1 (en) * 2018-04-11 2019-10-17 Oric Pharmaceuticals, Inc. Solid forms and formulations comprising a glucocorticoid receptor antagonist and uses thereof
WO2021163273A1 (en) * 2020-02-12 2021-08-19 Oric Pharmaceuticals, Inc. Uses of glucocorticoid receptor antagonists
US20230212215A1 (en) * 2020-05-08 2023-07-06 Trustees Of Dartmouth College Glucocorticoid receptor modulators
CN115915529A (zh) * 2021-09-30 2023-04-04 赛万特科技有限责任公司 发光控制方法、发光控制装置及发光装置
CN114230627B (zh) * 2021-12-31 2023-09-15 湖南新合新生物医药有限公司 一种倍他米松环氧水解物中间体的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2528434B1 (fr) 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
JP2785023B2 (ja) 1987-12-30 1998-08-13 ルセル―ユクラフ 17α位置を置換された17β―OH―19―ノルステロイドの新誘導体、その製造方法、その薬剤としての使用及びそれを含有する製薬組成物
JPH02188599A (ja) 1988-11-16 1990-07-24 Roussel Uclaf 3―ケト―デルタ―4,9―19―ノルステロイドから誘導される新物質及びそれらよりなる薬剤
DE3921059A1 (de) * 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
FR2651435A1 (fr) 1989-09-07 1991-03-08 Roussel Uclaf Nouvelle utilisation de composes anti-progestomimetiques.
DE4018167A1 (de) * 1990-06-01 1991-12-05 Schering Ag Verfahren zur herstellung von 10(beta)-h-steroiden
DE4042007A1 (de) * 1990-12-22 1992-06-25 Schering Ag 6,7-modifizierte-11(beta)-aryl-4-estrene
US5741787A (en) 1993-08-04 1998-04-21 Akzo Nobel N.V. Antiglucocorticoid steroids for the treatment of anxiety disorders
AU1439595A (en) 1993-12-22 1995-07-10 Salk Institute For Biological Studies, The Methods for reducing multidrug resistance
DK0806952T3 (da) 1995-02-02 2003-06-16 Schering Ag Progesteronantagonister til fremstillingen af lægemidler til behandling af dysfunktionelle uterine blødninger
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
CN1085078C (zh) * 1998-01-07 2002-05-22 沈志华 用于大月份引产的复合药物
US6512130B1 (en) * 2000-09-05 2003-01-28 Council Of Scientific And Industrial Research Mifepristone analogue, process for the preparation thereof and use thereof
EP1285927A3 (de) * 2001-08-16 2005-06-29 Schering Aktiengesellschaft Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
US7250408B2 (en) * 2002-12-16 2007-07-31 Bayer Schering Pharma Ag Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility
CN101421290B (zh) 2006-02-17 2012-09-19 詹森药业有限公司 用作孕酮受体调节剂的17-磷类固醇衍生物
CA2648139A1 (en) 2006-03-29 2007-11-08 The Regents Of The University Of California Diaryl thiohydantoin compounds and their use in the treatment of hyperproliferative disorders
US8569274B2 (en) 2007-04-20 2013-10-29 Preglem S.A. Progesterone antagonist and selective progesterone modulator in the treatment of excessive uterine bleeding
WO2012106514A2 (en) 2011-02-03 2012-08-09 Pop Test Cortisol Llc System and method for diagnosis and treatment
EP2545922A1 (en) 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
US20130029953A1 (en) 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
DK3111950T3 (da) 2012-02-24 2021-10-04 Univ Chicago Fremgangsmåder og sammensætninger relateret til glucocorticoidreceptorantagonisme og prostatacancer
EP2641602A1 (en) 2012-03-23 2013-09-25 PregLem S.A. Method for treating gynecological diseases
US9096641B2 (en) * 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
EP3079475B1 (en) * 2013-12-11 2020-10-07 Sloan-kettering Institute For Cancer Research Glucocorticoid inhibitors for treatment of prostate cancer
CN104530166B (zh) 2014-12-04 2016-08-24 陕西汉江药业集团股份有限公司 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
JP6906525B2 (ja) * 2015-12-23 2021-07-21 オリック ファーマシューティカルズ,インク. グルココルチコイド受容体の阻害剤
WO2017112909A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
CN110099915A (zh) 2016-10-07 2019-08-06 欧瑞克制药公司 糖皮质激素受体抑制剂
US12233073B2 (en) 2017-06-09 2025-02-25 Regents Of The University Of Minnesota Skin care formulations and skin cancer treatment
WO2019200156A1 (en) 2018-04-11 2019-10-17 Oric Pharmaceuticals, Inc. Solid forms and formulations comprising a glucocorticoid receptor antagonist and uses thereof

Similar Documents

Publication Publication Date Title
JP2019533651A5 (enExample)
JP2019501204A5 (enExample)
EP4219563A3 (en) Methods of treating cancer with anti-pd-1 antibodies
JP2017516775A5 (enExample)
JP2013520442A5 (enExample)
JP2019516711A5 (enExample)
JP2018508512A5 (enExample)
JP2016501221A5 (enExample)
JP2015534577A5 (enExample)
JP2015534578A5 (enExample)
JP2015500225A5 (enExample)
JP2016514689A5 (enExample)
JP2015534580A5 (enExample)
JP2016502504A5 (enExample)
JP2016528246A5 (enExample)
RU2017133273A (ru) Ингибиторы pd-1 / pd-l1 для лечения рака
MX2016008362A (es) Combinaciones farmaceuticas.
JP2012153722A5 (enExample)
JP2015534579A5 (enExample)
JP2018504418A5 (enExample)
JP2007526455A5 (enExample)
JP2014510729A5 (enExample)
JP2019532047A5 (enExample)
JP2017518291A5 (enExample)
JP2016513696A5 (enExample)